PARP-1 involvement in neurodegeneration: A focus on Alzheimer's and Parkinson's diseases

Mechanisms of Ageing and Development

Volumn 146-148, Issue , 2015, Pages 53-64

  Martire, Sara ^a   Mosca, Luciana ^a   d'Erme, Maria ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alzheimer's disease; Mitochondria; Parkinson's disease; Poly(ADP ribose)polymerase

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BCL 2; PROTEIN P53; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; BIOENERGY; BRAIN MITOCHONDRION; DEGENERATIVE DISEASE; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME STRUCTURE; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MITOPHAGY; MOLECULAR PATHOLOGY; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; ANIMAL; ENERGY METABOLISM; ENZYMOLOGY; GENETICS; METABOLISM; OXIDATIVE STRESS; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; ENERGY METABOLISM; HUMANS; OXIDATIVE STRESS; PARKINSON DISEASE; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84927930923     PISSN: 00476374     EISSN: 18726216     Source Type: Journal    
DOI: 10.1016/j.mad.2015.04.001     Document Type: Review

References (198)

1. Abd Elmageed Z.Y., Naura A.S., Errami Y., Zerfaoui M. The poly(ADP-ribose) polymerases (PARPs): new roles in intracellular transport. Cell. Signalling 2012, 24:1-8.
2. Abeti R., Abramov A.Y., Duchen M.R. Beta-amyloid activates PARP causing astrocytic metabolic failure and neuronal death. Brain: J. Neurol. 2011, 134:1658-1672.
3. Adamczyk A., Czapski G.A., Jesko H., Strosznajder R.P. Non A beta component of Alzheimer's disease amyloid and amyloid beta peptides evoked poly(ADP-ribose) polymerase-dependent release of apoptosis-inducing factor from rat brain mitochondria. J. Physiol. Pharmacol.: Off. J. Pol. Physiol. Soc. 2005, 56(Suppl. 2):5-13.
4. Adamczyk A., Kazmierczak A. Alpha-synuclein inhibits poly(ADP-ribose) polymerase-1 (PARP-1) activity via NO-dependent pathway. Folia Neuropathol. 2009, 47:247-251.
5. Adamczyk A., Kazmierczak A., Czapski G.A., Strosznajder J.B. Alpha-synuclein induced cell death in mouse hippocampal (HT22) cells is mediated by nitric oxide-dependent activation of caspase-3. FEBS Lett. 2010, 584:3504-3508.
6. Alano C.C., Garnier P., Ying W., Higashi Y., Kauppinen T.M., Swanson R.A. NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J. Neurosci.: Off. J. Soc. Neurosci. 2010, 30:2967-2978.
7. Altmeyer M., Messner S., Hassa P.O., Fey M., Hottiger M.O. Molecular mechanism of poly(ADP-ribosyl) ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites. Nucleic Acids Res. 2009, 37:3723-3738.
8. Ame J.C., Spenlehauer C., de Murcia G. The PARP superfamily. BioEssays: News Rev Mole Cell. Dev. Biol. 2004, 26:882-893.
9. Andrabi S.A., Kang H.C., Haince J.F., Lee Y.I., Zhang J., Chi Z., West A.B., Koehler R.C., Poirier G.G., Dawson T.M., Dawson V.L. Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death. Nat. Med. 2011, 17:692-699.
10. Andrabi S.A., Kim N.S., Yu S.W., Wang H., Koh D.W., Sasaki M., Klaus J.A., Otsuka T., Zhang Z., Koehler R.C., Hurn P.D., Poirier G.G., Dawson V.L., Dawson T.M. Poly(ADP-ribose) (PAR) polymer is a death signal. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:18308-18313.
11. Andrabi S.A., Umanah G.K., Chang C., Stevens D.A., Karuppagounder S.S., Gagne J.P., Poirier G.G., Dawson V.L., Dawson T.M. Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:10209-10214.
12. Angelova P.R., Abramov A.Y. Interaction of neurons and astrocytes underlies the mechanism of Abeta-induced neurotoxicity. Biochem. Soc. Trans. 2014, 42:1286-1290.
13. Anglade P., Vyas S., Javoy-Agid F., Herrero M.T., Michel P.P., Marquez J., Mouatt-Prigent A., Ruberg M., Hirsch E.C., Agid Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 1997, 12:25-31.
14. Aredia F., Scovassi A.I. Involvement of PARPs in cell death. Front. Biosci. (Elite Ed.) 2014, 6:308-317.
15. Aredia F., Scovassi A.I. Poly(ADP-ribose): a signaling molecule in different paradigms of cell death. Biochem. Pharmacol. 2014, 92:157-163.
16. Bai P., Canto C. The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. Cell Metab. 2012, 16:290-295.
17. Bai P., Canto C., Oudart H., Brunyanszki A., Cen Y., Thomas C., Yamamoto H., Huber A., Kiss B., Houtkooper R.H., Schoonjans K., Schreiber V., Sauve A.A., Menissier-de Murcia J., Auwerx J. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 2011, 13:461-468.
18. Bai P., Nagy L., Fodor T., Liaudet L., Pacher P. Poly(ADP-ribose) polymerases as modulators of mitochondrial activity. Trends Endocrinol. Metab.: TEM 2015, 26:75-83.
19. Bai P., Virag L. Role of poly(ADP-ribose) polymerases in the regulation of inflammatory processes. FEBS Lett. 2012, 586:3771-3777.
20. Beal M.F. Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 2005, 58:495-505.
21. Beneke S. Regulation of chromatin structure by poly(ADP-ribosyl) ation. Front. Genet. 2012, 3:169.
22. Berger N.A. Poly(ADP-ribose) in the cellular response to DNA damage. Radiat. Res. 1985, 101:4-15.
23. Bork P., Hofmann K., Bucher P., Neuwald A.F., Altschul S.F., Koonin E.V. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 1997, 11:68-76.
24. Broniowska K.A., Diers A.R., Corbett J.A., Hogg N. Effect of nitric oxide on naphthoquinone toxicity in endothelial cells: role of bioenergetic dysfunction and poly(ADP-ribose) polymerase activation. Biochemistry 2013, 52:4364-4372.
25. Burguillos M.A., Hajji N., Englund E., Persson A., Cenci A.M., Machado A., Cano J., Joseph B., Venero J.L. Apoptosis-inducing factor mediates dopaminergic cell death in response to LPS-induced inflammatory stimulus: evidence in Parkinson's disease patients. Neurobiol. Dis. 2011, 41:177-188.
26. Burkle A. Poly(ADP-ribose). The most elaborate metabolite of NAD+. FEBS J. 2005, 272:4576-4589.
27. Burkle A. DNA repair and PARP in aging. Free Radical Res. 2006, 40:1295-1302.
28. Burkle A., Virag L. Poly(ADP-ribose): PARadigms and PARadoxes. Mol. Aspects Med. 2013, 34:1046-1065.
29. Canto C., Auwerx J. Interference between PARPs and SIRT1: a novel approach to healthy ageing?. Aging 2011, 3:543-547.
30. Canto C., Auwerx J. NAD+ as a signaling molecule modulating metabolism. Cold Spring Harbor Symp. Quant. Biol. 2011, 76:291-298.
31. Canto C., Sauve A.A., Bai P. Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes. Mol. Aspects Med. 2013, 34:1168-1201.
32. Cenini G., Cecchi C., Pensalfini A., Bonini S.A., Ferrari-Toninelli G., Liguri G., Memo M., Uberti D. Generation of reactive oxygen species by beta amyloid fibrils and oligomers involves different intra/extracellular pathways. Amino Acids 2010, 38:1101-1106.
33. Chaturvedi R.K., Flint Beal M. Mitochondrial diseases of the brain. Free Radical Biol. Med. 2013, 63:1-29.
34. Cherney B.W., McBride O.W., Chen D.F., Alkhatib H., Bhatia K., Hensley P., Smulson M.E. cDNA sequence, protein structure, and chromosomal location of the human gene for poly(ADP-ribose) polymerase. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:8370-8374.
35. Chiarugi A., Dolle C., Felici R., Ziegler M. The NAD metabolome - a key determinant of cancer cell biology. Nat. Rev. Cancer 2012, 12:741-752.
36. Chiarugi A., Moskowitz M.A. Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders. J. Neurochem. 2003, 85:306-317.
37. Conn K.J., Ullman M.D., Eisenhauer P.B., Fine R.E., Wells J.M. Decreased expression of the NADH:ubiquinone oxidoreductase (complex I) subunit 4 in 1-methyl-4-phenylpyridinium-treated human neuroblastoma SH-SY5Y cells. Neurosci. Lett. 2001, 306:145-148.
38. Cosi C., Chopin P., Marien M. Benzamide, an inhibitor of poly(ADP-ribose) polymerase, attenuates methamphetamine-induced dopamine neurotoxicity in the C57B1/6N mouse. Brain Res. 1996, 735:343-348.
39. Cregan S.P., Fortin A., MacLaurin J.G., Callaghan S.M., Cecconi F., Yu S.W., Dawson T.M., Dawson V.L., Park D.S., Kroemer G., Slack R.S. Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J. Cell Biol. 2002, 158:507-517.
40. D'Amours D., Desnoyers S., D'Silva I., Poirier G.G. Poly(ADP-ribosyl) ation reactions in the regulation of nuclear functions. Biochem. J. 1999, 342(Pt 2):249-268.
41. David K.K., Andrabi S.A., Dawson T.M., Dawson V.L. Parthanatos, a messenger of death. Front. Biosci. 2009, 14:1116-1128.
42. Davidovic L., Vodenicharov M., Affar E.B., Poirier G.G. Importance of poly(ADP-ribose) glycohydrolase in the control of poly(ADP-ribose) metabolism. Exp. Cell Res. 2001, 268:7-13.
43. Dawson T.M., Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302:819-822.
44. Dawson V.L., Dawson T.M. Nitric oxide neurotoxicity. J. Chem. Neuroanat. 1996, 10:179-190.
45. de Murcia G., Menissier de Murcia J. Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem. Sci. 1994, 19:172-176.
46. Desmarais Y., Menard L., Lagueux J., Poirier G.G. Enzymological properties of poly(ADP-ribose) polymerase: characterization of automodification sites and NADase activity. Biochim. Biophys. Acta 1991, 1078:179-186.
47. Devalaraja-Narashimha K., Padanilam B.J. PARP1 deficiency exacerbatesdiet-induced obesity in mice. J. Endocrinol. 2010, 205:243-252.
48. Dolle C., Rack J.G., Ziegler M. NAD and ADP-ribose metabolism in mitochondria. FEBS J. 2013, 280:3530-3541.
49. Donmez G., Guarente L. Aging and disease: connections to sirtuins. Aging Cell 2010, 9:285-290.
50. Dragicevic N., Mamcarz M., Zhu Y., Buzzeo R., Tan J., Arendash G.W., Bradshaw P.C. Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice. J. Alzheimer's Dis.: JAD 2010, 20(Suppl. 2):S535-S550.
51. Dutta C., Day T., Kopp N., van Bodegom D., Davids M.S., Ryan J., Bird L., Kommajosyula N., Weigert O., Yoda A., Fung H., Brown J.R., Shapiro G.I., Letai A., Weinstock D.M. BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer Res. 2012, 72:4193-4203.
52. Eiyama A., Okamoto K. PINK1/Parkin-mediated mitophagy in mammalian cells. Curr. Opin. Cell Biol. 2015, 33C:95-101.
53. Fang E.F., Scheibye-Knudsen M., Brace L.E., Kassahun H., SenGupta T., Nilsen H., Mitchell J.R., Croteau D.L., Bohr V.A. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD(+)/SIRT1 reduction. Cell 2014, 157:882-896.
54. Fatokun A.A., Dawson V.L., Dawson T.M. Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities. Br. J. Pharmacol. 2014, 171:2000-2016.
55. Galluzzi L., Vitale I., Abrams J.M., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., Dawson T.M., Dawson V.L., El-Deiry W.S., Fulda S., Gottlieb E., Green D.R., Hengartner M.O., Kepp O., Knight R.A., Kumar S., Lipton S.A., Lu X., Madeo F., Malorni W., Mehlen P., Nunez G., Peter M.E., Piacentini M., Rubinsztein D.C., Shi Y., Simon H.U., Vandenabeele P., White E., Yuan J., Zhivotovsky B., Melino G., Kroemer G. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012, 19:107-120.
56. Gao L., Gao H., Zhou H., Xu Y. Gene expression profiling analysis of the putamen for the investigation of compensatory mechanisms in Parkinson's disease. BMC Neurol. 2013, 13:181.
57. Ghavami S., Shojaei S., Yeganeh B., Ande S.R., Jangamreddy J.R., Mehrpour M., Christoffersson J., Chaabane W., Moghadam A.R., Kashani H.H., Hashemi M., Owji A.A., Los M.J. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog. Neurobiol. 2014, 112:24-49.
58. Ghosh A., Roy A., Liu X., Kordower J.H., Mufson E.J., Hartley D.M., Ghosh S., Mosley R.L., Gendelman H.E., Pahan K. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:18754-18759.
59. Giansanti V., Dona F., Tillhon M., Scovassi A.I. PARP inhibitors: new tools to protect from inflammation. Biochem. Pharmacol. 2010, 80:1869-1877.
60. Harper J.D., Wong S.S., Lieber C.M., Lansbury P.T. Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry 1999, 38:8972-8980.
61. Harraz M.M., Dawson T.M., Dawson V.L. Advances in neuronal cell death 2007. Stroke: J. Cereb. Circ. 2008, 39:286-288.
62. Hassa P.O., Hottiger M.O. A role of poly (ADP-ribose) polymerase in NF-kappaB transcriptional activation. Biol. Chem. 1999, 380:953-959.
63. Hatakeyama K., Nemoto Y., Ueda K., Hayaishi O. Purification and characterization of poly(ADP-ribose) glycohydrolase. Different modes of action on large and small poly(ADP-ribose). J. Biol. Chem. 1986, 261:14902-14911.
64. Hayashi M. Oxidative stress in developmental brain disorders. Neuropathology 2009, 29:1-8.
65. Hegedus C., Virag L. Inputs and outputs of poly(ADP-ribosyl) ation: relevance to oxidative stress. Redox Biol. 2014, 2C:978-982.
66. Hottiger M.O., Hassa P.O., Luscher B., Schuler H., Koch-Nolte F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem. Sci. 2010, 35:208-219.
67. Houtkooper R.H., Canto C., Wanders R.J., Auwerx J. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr. Rev. 2010, 31:194-223.
68. Huber A., Stuchbury G., Burkle A., Burnell J., Munch G. Neuroprotective therapies for Alzheimer's disease. Curr. Pharm. Des. 2006, 12:705-717.
69. Huh S.H., Chung Y.C., Piao Y., Jin M.Y., Son H.J., Yoon N.S., Hong J.Y., Pak Y.K., Kim Y.S., Hong J.K., Hwang O., Jin B.K. Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease. J. Immunol. 2011, 187:960-969.
70. Irizarry M.C., Soriano F., McNamara M., Page K.J., Schenk D., Games D., Hyman B.T. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 1997, 17:7053-7059.
71. Isopi E., Granzotto A., Corona C., Bomba M., Ciavardelli D., Curcio M., Canzoniero L.M., Navarra R., Lattanzio R., Piantelli M., Sensi S.L. Pyruvate prevents the development of age-dependent cognitive deficits in a mouse model of Alzheimer's disease without reducing amyloid and tau pathology. Neurobiol. Dis. 2014, (November 28). arxiv:/pii:S0969-9961(14)00358-1.
72. Itoh M., Hayashi M., Shioda K., Minagawa M., Isa F., Tamagawa K., Morimatsu Y., Oda M. Neurodegeneration in hereditary nucleotide repair disorders. Brain Dev. 1999, 21:326-333.
73. Iwashita A., Tojo N., Matsuura S., Yamazaki S., Kamijo K., Ishida J., Yamamoto H., Hattori K., Matsuoka N., Mutoh S. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia. J. Pharmacol. Exp. Ther. 2004, 310:425-436.
74. Jung S., Miranda E.A., de Murcia J.M., Niedergang C., Delarue M., Schulz G.E., de Murcia G.M. Crystallization and X-ray crystallographic analysis of recombinant chicken poly(ADP-ribose) polymerase catalytic domain produced in Sf9 insect cells. J. Mol. Biol. 1994, 244:114-116.
75. Kaltschmidt B., Uherek M., Volk B., Baeuerle P.A., Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:2642-2647.
76. Kaltschmidt B., Uherek M., Wellmann H., Volk B., Kaltschmidt C. Inhibition of NF-kappaB potentiates amyloid beta-mediated neuronal apoptosis. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:9409-9414.
77. Kameshita I., Matsuda Z., Taniguchi T., Shizuta Y. Poly (ADP-Ribose) synthetase. Separation and identification of three proteolytic fragments as the substrate-binding domain the DNA-binding domain, and the automodification domain. J. Biol. Chem. 1984, 259:4770-4776.
78. Karbowski M., Neutzner A. Neurodegeneration as a consequence of failed mitochondrial maintenance. Acta Neuropathol. 2012, 123:157-171.
79. Kauppinen T.M., Gan L., Swanson R.A. Poly(ADP-ribose) polymerase-1-induced NAD(+) depletion promotes nuclear factor-kappaB transcriptional activity by preventing p65 de-acetylation. Biochim. Biophys. Acta 2013, 1833:1985-1991.
80. Kauppinen T.M., Swanson R.A. The role of poly(ADP-ribose) polymerase-1 in CNS disease. Neuroscience 2007, 145:1267-1272.
81. Kauppinen T.M., Suh S.W., Higashi Y., Berman A.E., Escartin C., Won S.J., Wang C., Cho S.H., Gan L., Swanson R.A. Poly(ADP-ribose) polymerase-1 modulates microglial responses to amyloid beta. J. Neuroinflammation 2011, 8:152.
82. Kesidou E., Lagoudaki R., Touloumi O., Poulatsidou K.N., Simeonidou C. Autophagy and neurodegenerative disorders. Neural Regener. Res. 2013, 8:2275-2283.
83. Kim S.H., Lu H.F., Alano C.C. Neuronal Sirt3 protects against excitotoxic injury in mouse cortical neuron culture. PLoS One 2011, 6:e14731.
84. Kim T.W., Cho H.M., Choi S.Y., Suguira Y., Hayasaka T., Setou M., Koh H.C., Hwang E.M., Park J.Y., Kang S.J., Kim H.S., Kim H., Sun W. (ADP-ribose) polymerase 1 and AMP-activated protein kinase mediate progressive dopaminergic neuronal degeneration in a mouse model of Parkinson's disease. Cell Death Dis. 2013, 4:e919.
85. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392:605-608.
86. Koh D.W., Dawson T.M., Dawson V.L. Mediation of cell death by poly(ADP-ribose) polymerase-1. Pharmacol. Res. 2005, 52:5-14.
87. Krietsch J., Rouleau M., Pic E., Ethier C., Dawson T.M., Dawson V.L., Masson J.Y., Poirier G.G., Gagne J.P. Reprogramming cellular events by poly(ADP-ribose)-binding proteins. Mol. Aspects Med. 2013, 34:1066-1087.
88. Kumari S.R., Mendoza-Alvarez H., Alvarez-Gonzalez R. Functional interactions of p53 with poly(ADP-ribose) polymerase (PARP) during apoptosis following DNA damage: covalent poly(ADP-ribosyl) ation of p53 by exogenous PARP and noncovalent binding of p53 to the M(r) 85,000 proteolytic fragment. Cancer Res. 1998, 58:5075-5078.
89. Kurosaki T., Ushiro H., Mitsuuchi Y., Suzuki S., Matsuda M., Matsuda Y., Katunuma N., Kangawa K., Matsuo H., Hirose T., et al. Primary structure of human poly(ADP-ribose) synthetase as deduced from cDNA sequence. J. Biol. Chem. 1987, 262:15990-15997.
90. Kwong J.Q., Beal M.F., Manfredi G. The role of mitochondria in inherited neurodegenerative diseases. J. Neurochem. 2006, 97:1659-1675.
91. Langelier M.F., Servent K.M., Rogers E.E., Pascal J.M. A third zinc-binding domain of human poly(ADP-ribose) polymerase-1 coordinates DNA-dependent enzyme activation. J. Biol. Chem. 2008, 283:4105-4114.
92. Larson M.E., Lesne S.E. Soluble Abeta oligomer production and toxicity. J. Neurochem. 2012, 120(Suppl. 1):125-139.
93. Lee J.Y., Kim Y.H., Koh J.Y. Protection by pyruvate against transient forebrain ischemia in rats. J. Neurosci.: Off. J. Soc. Neurosci. 2001, 21:RC171.
94. Li R., Yang L., Lindholm K., Konishi Y., Yue X., Hampel H., Zhang D., Shen Y. Tumor necrosis factor death receptor signaling cascade is required for amyloid-beta protein-induced neuron death. J. Neurosci. 2004, 24:1760-1771.
95. Love S., Barber R., Wilcock G.K. Increased poly(ADP-ribosyl) ation of nuclear proteins in Alzheimer's disease. Brain: J. Neurol. 1999, 122(Pt 2):247-253.
96. Maciag A.E., Holland R.J., Kim Y., Kumari V., Luthers C.E., Sehareen W.S., Biswas D., Morris N.L., Ji X., Anderson L.M., Saavedra J.E., Keefer L.K. Nitric oxide (NO) releasing poly ADP-ribose polymerase 1 (PARP-1) inhibitors targeted to glutathione S-transferase P1-overexpressing cancer cells. J. Med. Chem. 2014, 57:2292-2302.
97. Mandir A.S., Przedborski S., Jackson-Lewis V., Wang Z.Q., Simbulan-Rosenthal C.M., Smulson M.E., Hoffman B.E., Guastella D.B., Dawson V.L., Dawson T.M. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:5774-5779.
98. Marques O., Outeiro T.F. Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis. 2012, 3:e350.
99. Marsischky G.T., Wilson B.A., Collier R.J. Role of glutamic acid 988 of human poly-ADP-ribose polymerase in polymer formation. Evidence for active site similarities to the ADP-ribosylating toxins. J. Biol. Chem. 1995, 270:3247-3254.
100. Martin L.J. Biology of mitochondria in neurodegenerative diseases. Prog. Mol. Biol. Transl. Sci. 2012, 107:355-415.
101. Martire S., Fuso A., Rotili D., Tempera I., Giordano C., De Zottis I., Muzi A., Vernole P., Graziani G., Lococo E., Faraldi M., Maras B., Scarpa S., Mosca L., d'Erme M. PARP-1 modulates amyloid beta peptide-induced neuronal damage. PLoS One 2013, 8:e72169.
102. Mattson M.P., Barger S.W., Furukawa K., Bruce A.J., Wyss-Coray T., Mark R.J., Mucke L. Cellular signaling roles of TGF beta: TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Brain Res. Brain Res. Rev. 1997, 23:47-61.
103. Mattson M.P., Camandola S. NF-kappaB in neuronal plasticity and neurodegenerative disorders. J. Clin. Invest. 2001, 107:247-254.
104. Mazen A., Menissier-de Murcia J., Molinete M., Simonin F., Gradwohl G., Poirier G., de Murcia G. Poly(ADP-ribose) polymerase: a novel finger protein. Nucleic Acids Res. 1989, 17:4689-4698.
105. McBride H.M., Neuspiel M., Wasiak S. Mitochondria: more than just a powerhouse. Curr. Biol. 2006, 16:R551-560.
106. Miramar M.D., Costantini P., Ravagnan L., Saraiva L.M., Haouzi D., Brothers G., Penninger J.M., Peleato M.L., Kroemer G., Susin S.A. NADH oxidase activity of mitochondrial apoptosis-inducing factor. J. Biol. Chem. 2001, 276:16391-16398.
107. Mochizuki H., Goto K., Mori H., Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J. Neurol. Sci. 1996, 137:120-123.
108. Modis K., Asimakopoulou A., Coletta C., Papapetropoulos A., Szabo C. Oxidative stress suppresses the cellular bioenergetic effect of the 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway. Biochem. Biophys. Res. Commun. 2013, 433:401-407.
109. Modis K., Gero D., Erdelyi K., Szoleczky P., DeWitt D., Szabo C. Cellular bioenergetics is regulated by PARP1 under resting conditions and during oxidative stress. Biochem. Pharmacol. 2012, 83:633-643.
110. Mogi M., Harada M., Kondo T., Mizuno Y., Narabayashi H., Riederer P., Nagatsu T. bcl-2 protein is increased in the brain from parkinsonian patients. Neurosci. Lett. 1996, 215:137-139.
111. Mohamed J.S., Wilson J.C., Myers M.J., Sisson K.J., Alway S.E. Dysregulation of SIRT-1 in aging mice increases skeletal muscle fatigue by a PARP-1-dependent mechanism. Aging 2014, 6:820-834.
112. Mosca L., Lendaro E., d'Erme M., Marcellini S., Moretti S., Rosei M.A. 5-S-Cysteinyl-dopamine effect on the human dopaminergic neuroblastoma cell line SH-SY5Y. Neurochem. Int. 2006, 49:262-269.
113. Natsume A., Mata M., Goss J., Huang S., Wolfe D., Oligino T., Glorioso J., Fink D.J. Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration. Exp. Neurol. 2001, 169:231-238.
114. Nilsen L.H., Witter M.P., Sonnewald U. Neuronal and astrocytic metabolism in a transgenic rat model of Alzheimer's disease. J. Cereb. Blood Flow Metab.: Off. J. Int. Soc. Cereb. Blood Flow Metab. 2014, 34:906-914.
115. Novak I. Mitophagy: a complex mechanism of mitochondrial removal. Antioxid. Redox Signaling 2012, 17:794-802.
116. O'Neill L.A., Kaltschmidt C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci. 1997, 20:252-258.
117. Offen D., Beart P.M., Cheung N.S., Pascoe C.J., Hochman A., Gorodin S., Melamed E., Bernard R., Bernard O. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:5789-5794.
118. Ogata N., Ueda K., Kawaichi M., Hayaishi O. Poly(ADP-ribose) synthetase, a main acceptor of poly(ADP-ribose) in isolated nuclei. J. Biol. Chem. 1981, 256:4135-4137.
119. Ohyagi Y., Asahara H., Chui D.H., Tsuruta Y., Sakae N., Miyoshi K., Yamada T., Kikuchi H., Taniwaki T., Murai H., Ikezoe K., Furuya H., Kawarabayashi T., Shoji M., Checler F., Iwaki T., Makifuchi T., Takeda K., Kira J., Tabira T. Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease. FASEB J. 2005, 19:255-257.
120. Oliver F.J., Menissier-de Murcia J., Nacci C., Decker P., Andriantsitohaina R., Muller S., de la Rubia G., Stoclet J.C., de Murcia G. Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J. 1999, 18:4446-4454.
121. Outeiro T.F., Grammatopoulos T.N., Altmann S., Amore A., Standaert D.G., Hyman B.T., Kazantsev A.G. Pharmacological inhibition of PARP-1 reduces alpha-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models. Biochem. Biophys. Res. Commun. 2007, 357:596-602.
122. Pacher P., Szabó C. Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid. Redox Signaling 2005, 7:1568-1580.
123. Pacher P., Szabo C. Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. Am. J. Pathol. 2008, 173:2-13.
124. Pan L.Z., Ahn D.G., Sharif T., Clements D., Gujar S.A., Lee P.W. The NAD+ synthesizing enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) is a p53 downstream target. Cell Cycle 2014, 13:1041-1048.
125. Paradis E., Douillard H., Koutroumanis M., Goodyer C., LeBlanc A. Amyloid beta peptide of Alzheimer's disease downregulates Bcl-2 and upregulates bax expression in human neurons. J. Neurosci. 1996, 16:7533-7539.
126. Parker W.D., Parks J.K., Swerdlow R.H. Complex I deficiency in Parkinson's disease frontal cortex. Brain Res. 2008, 1189:215-218.
127. Pasinetti G.M., Wang J., Marambaud P., Ferruzzi M., Gregor P., Knable L.A., Ho L. Neuroprotective and metabolic effects of resveratrol: therapeutic implications for Huntington's disease and other neurodegenerative disorders. Exp. Neurol. 2011, 232:1-6.
128. Peralta-Leal A., Rodriguez-Vargas J.M., Aguilar-Quesada R., Rodriguez M.I., Linares J.L., de Almodovar M.R., Oliver F.J. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Free Radical Biol. Med. 2009, 47:13-26.
129. Perina D., Mikoc A., Ahel J., Cetkovic H., Zaja R., Ahel I. Distribution of protein poly(ADP-ribosyl) ation systems across all domains of life. DNA Repair 2014, 23:4-16.
130. Pillai J.B., Isbatan A., Imai S., Gupta M.P. Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity. J. Biol. Chem. 2005, 280:43121-43130.
131. Pithadia A.S., Lim M.H. Metal-associated amyloid-beta species in Alzheimer's disease. Curr. Opin. Chem. Biol. 2012, 16:67-73.
132. Pizzi M., Goffi F., Boroni F., Benarese M., Perkins S.E., Liou H.C., Spano P. Opposing roles for NF-kappa B/Rel factors p65 and c-Rel in the modulation of neuron survival elicited by glutamate and interleukin-1beta. J. Biol. Chem. 2002, 277:20717-20723.
133. Pizzi M., Sarnico I., Boroni F., Benetti A., Benarese M., Spano P.F. Inhibition of IkappaBalpha phosphorylation prevents glutamate-induced NF-kappaB activation and neuronal cell death. Acta Neurochir. Suppl. 2005, 93:59-63.
134. Przedborski S., Chen Q., Vila M., Giasson B.I., Djaldatti R., Vukosavic S., Souza J.M., Jackson-Lewis V., Lee V.M., Ischiropoulos H. Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J. Neurochem. 2001, 76:637-640.
135. Reitz C., Brayne C., Mayeux R. Epidemiology of Alzheimer disease. Nat. Rev. Neurol. 2011, 7:137-152.
136. Rekha K.R., Selvakumar G.P. Gene expression regulation of Bcl2, Bax and cytochrome-C by geraniol on chronic MPTP/probenecid induced C57BL/6 mice model of Parkinson's disease. Chem. Biol. Interact. 2014, 217:57-66.
137. Rhein V., Song X., Wiesner A., Ittner L.M., Baysang G., Meier F., Ozmen L., Bluethmann H., Drose S., Brandt U., Savaskan E., Czech C., Gotz J., Eckert A. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:20057-20062.
138. Rolli V., O'Farrell M., Menissier-de Murcia J., de Murcia G. Random mutagenesis of the poly(ADP-ribose) polymerase catalytic domain reveals amino acids involved in polymer branching. Biochemistry 1997, 36:12147-12154.
139. Rom S., Zuluaga-Ramirez V., Dykstra H., Reichenbach N.L., Ramirez S.H., Persidsky Y. Poly(ADP-ribose) polymerase -1 inhibition in brain endothelium protects the blood-brain barrier under physiologic and neuroinflammatory conditions. J. Cereb. Blood Flow Metab.: Off. J. Int. Soc. Cereb. Blood Flow Metab. 2015, 35:28-36.
140. Ruf A., Mennissier de Murcia J., de Murcia G., Schulz G.E. Structure of the catalytic fragment of poly(AD-ribose) polymerase from chicken. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:7481-7485.
141. Saraiva L.M., Seixas da Silva G.S., Galina A., da-Silva W.S., Klein W.L., Ferreira S.T., De Felice F.G. Amyloid-beta triggers the release of neuronal hexokinase 1 from mitochondria. PLoS One 2010, 5:e15230.
142. Satoh M.S., Lindahl T. Role of poly(ADP-ribose) formation in DNA repair. Nature 1992, 356:356-358.
143. Satpute R., Lomash V., Kaushal M., Bhattacharya R. Neuroprotective effects of alpha-ketoglutarate and ethyl pyruvate against motor dysfunction and oxidative changes caused by repeated 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine exposure in mice. Hum. Exp. Toxicol. 2013, 32:747-758.
144. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989, 1:1269.
145. Scheibye-Knudsen M., Fang E.F., Croteau D.L., Bohr V.A. Contribution of defective mitophagy to the neurodegeneration in DNA repair-deficient disorders. Autophagy 2014, 10:1468-1469.
146. Seo J.H., Rah J.C., Choi S.H., Shin J.K., Min K., Kim H.S., Park C.H., Kim S., Kim E.M., Lee S.H., Lee S., Suh S.W., Suh Y.H. Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J. 2002, 16:1826-1828.
147. Simonin F., Hofferer L., Panzeter P.L., Muller S., de Murcia G., Althaus F.R. The carboxyl-terminal domain of human poly(ADP-ribose) polymerase. Overproduction in Escherichia coli, large scale purification, and characterization. J. Biol. Chem. 1993, 268:13454-13461.
148. Soane L., Kahraman S., Kristian T., Fiskum G. Mechanisms of impaired mitochondrial energy metabolism in acute and chronic neurodegenerative disorders. J. Neurosci. Res. 2007, 85:3407-3415.
149. Soos J., Engelhardt J.I., Siklos L., Havas L., Majtenyi K. The expression of PARP, NF-kappa B and parvalbumin is increased in Parkinson disease. Neuroreport 2004, 15:1715-1718.
150. Steffen J.D., Brody J.R., Armen R.S., Pascal J.M. Structural implications for selective targeting of PARPs. Front. Oncol. 2013, 3:301.
151. Storch A., Kaftan A., Burkhardt K., Schwarz J. 1-Methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (salsolinol) is toxic to dopaminergic neuroblastoma SH-SY5Y cells via impairment of cellular energy metabolism. Brain Res. 2000, 855:67-75.
152. Strosznajder J.B., Cieslik M., Cakala M., Jesko H., Eckert A., Strosznajder R.P. Lipoxygenases and poly(ADP-ribose) polymerase in amyloid beta cytotoxicity. Neurochem. Res. 2011, 36:839-848.
153. Strosznajder J.B., Czapski G.A., Adamczyk A., Strosznajder R.P. Poly(ADP-ribose) polymerase-1 in amyloid beta toxicity and Alzheimer's disease. Mol. Neurobiol. 2012, 46:78-84.
154. Strosznajder J.B., Jesko H., Strosznajder R.P. Effect of amyloid beta peptide on poly(ADP-ribose) polymerase activity in adult and aged rat hippocampus. Acta Biochim. Pol. 2000, 47:847-854.
155. Strosznajder R.P., Jesko H., Zambrzycka A. Poly(ADP-ribose) polymerase: the nuclear target in signal transduction and its role in brain ischemia-reperfusion injury. Mol. Neurobiol. 2005, 31:149-167.
156. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Snow B.E., Brothers G.M., Mangion J., Jacotot E., Costantini P., Loeffler M., Larochette N., Goodlett D.R., Aebersold R., Siderovski D.P., Penninger J.M., Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999, 397:441-446.
157. Swerdlow R.H., Burns J.M., Khan S.M. The Alzheimer's disease mitochondrial cascade hypothesis. J. Alzheimer's Dis.: JAD 2010, 20(Suppl. 2):S265-279.
158. Sykora P., Wilson D.M., Bohr V.A. Base excision repair in the mammalian brain: implication for age related neurodegeneration. Mech. Ageing Dev. 2013, 134:440-448.
159. Takeuchi A., Irizarry M.C., Duff K., Saido T.C., Hsiao Ashe K., Hasegawa M., Mann D.M., Hyman B.T., Iwatsubo T. Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am. J. Pathol. 2000, 157:331-339.
160. Tatton W.G., Chalmers-Redman R.M., Ju W.Y., Wadia J., Tatton N.A. Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription. J. Neural Transm. Suppl. 1997, 49:245-268.
161. Tempera I., Deng Z., Atanasiu C., Chen C.J., D'Erme M., Lieberman P.M. Regulation of Epstein-Barr virus OriP replication by poly(ADP-ribose) polymerase 1. J. Virol. 2010, 84:4988-4997.
162. Tillement L., Lecanu L., Papadopoulos V. Alzheimer's disease: effects of beta-amyloid on mitochondria. Mitochondrion 2011, 11:13-21.
163. Turunc Bayrakdar E., Uyanikgil Y., Kanit L., Koylu E., Yalcin A. Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in Abeta(1-42)-induced rat model of Alzheimer's disease. Free Radical Res. 2014, 48:146-158.
164. Uchida M., Hanai S., Uematsu N., Sawamoto K., Okano H., Miwa M., Uchida K. Genetic and functional analysis of PARP, a DNA strand break-binding enzyme. Mutat. Res. 2001, 477:89-96.
165. Ullrich O., Diestel A., Eyupoglu I.Y., Nitsch R. Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1. Nat. Cell Biol. 2001, 3:1035-1042.
166. Valenzuela M.T., Guerrero R., Nunez M.I., Ruiz De Almodovar J.M., Sarker M., de Murcia G., Oliver F.J. PARP-1 modifies the effectiveness of p53-mediated DNA damage response. Oncogene 2002, 21:1108-1116.
167. Valerio A., Boroni F., Benarese M., Sarnico I., Ghisi V., Bresciani L.G., Ferrario M., Borsani G., Spano P., Pizzi M. NF-kappaB pathway: a target for preventing beta-amyloid (Abeta)-induced neuronal damage and Abeta42 production. Eur. J. Neurosci. 2006, 23:1711-1720.
168. Vauzour D., Pinto J.T., Cooper A.J., Spencer J.P. The neurotoxicity of 5-S-cysteinyldopamine is mediated by the early activation of ERK1/2 followed by the subsequent activation of ASK1/JNK1/2 pro-apoptotic signalling. Biochem. J. 2014, 463:41-52.
169. Veuger S.J., Hunter J.E., Durkacz B.W. Ionizing radiation-induced NF-kappaB activation requires PARP-1 function to confer radioresistance. Oncogene 2009, 28:832-842.
170. Virag L., Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 2002, 54:375-429.
171. Viswanath V., Wu Y., Boonplueang R., Chen S., Stevenson F.F., Yantiri F., Yang L., Beal M.F., Andersen J.K. Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J. Neurosci. 2001, 21:9519-9528.
172. Wallace D.C. Mitochondria and cancer: Warburg addressed. Cold Spring Harbor Symp. Quant. Biol. 2005, 70:363-374.
173. Wallace D.C., Ruiz-Pesini E., Mishmar D. mtDNA variation, climatic adaptation, degenerative diseases, and longevity. Cold Spring Harbor Symp. Quant. Biol. 2003, 68:479-486.
174. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
175. Wang H., Shimoji M., Yu S.W., Dawson T.M., Dawson V.L. Apoptosis inducing factor and PARP-mediated injury in the MPTP mouse model of Parkinson's disease. Ann. N. Y. Acad. Sci. 2003, 991:132-139.
176. Wang Q., van Hoecke M., Tang X.N., Lee H., Zheng Z., Swanson R.A., Yenari M.A. Pyruvate protects against experimental stroke via an anti-inflammatory mechanism. Neurobiol. Dis. 2009, 36:223-231.
177. Wang X., Takata T., Bai X., Ou F., Yokono K., Sakurai T. Pyruvate prevents the inhibition of the long-term potentiation induced by amyloid-beta through protein phosphatase 2A inactivation. J. Alzheimer's Dis.: JAD 2012, 30:665-673.
178. Wang Y., Kim N.S., Haince J.F., Kang H.C., David K.K., Andrabi S.A., Poirier G.G., Dawson V.L., Dawson T.M. Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). Sci. Signaling 2011, 4:ra20.
179. Wang Z.Q., Auer B., Stingl L., Berghammer H., Haidacher D., Schweiger M., Wagner E.F. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev. 1995, 9:509-520.
180. Wesierska-Gadek J., Schmid G. Poly(ADP-ribose) polymerase-1 regulates the stability of the wild-type p53 protein. Cell. Mol. Biol. Lett. 2001, 6:117-140.
181. Wieler S., Gagne J.P., Vaziri H., Poirier G.G., Benchimol S. Poly(ADP-ribose) polymerase-1 is a positive regulator of the p53-mediated G1 arrest response following ionizing radiation. J. Biol. Chem. 2003, 278:18914-18921.
182. Wu M.F., Yin J.H., Hwang C.S., Tang C.M., Yang D.I. NAD attenuates oxidative DNA damages induced by amyloid beta-peptide in primary rat cortical neurons. Free Radical Res. 2014, 48:794-805.
183. Wu X.L., Wang P., Liu Y.H., Xue Y.X. Effects of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide on blood-brain barrier and dopaminergic neurons of rats with lipopolysaccharide-induced Parkinson's disease. J. Mol. Neurosci.: MN 2014, 53:1-9.
184. Yang N., Gong F., Sun L., Yang D., Han X., Ma C., Sun Y. Poly (ADP-ribose) polymerase-1 binds to BCL2 major breakpoint region and regulates BCL2 expression. J. Cell. Biochem. 2010, 110:1208-1218.
185. Yao J., Irwin R.W., Zhao L., Nilsen J., Hamilton R.T., Brinton R.D. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14670-14675.
186. Ye H., Cande C., Stephanou N.C., Jiang S., Gurbuxani S., Larochette N., Daugas E., Garrido C., Kroemer G., Wu H. DNA binding is required for the apoptogenic action of apoptosis inducing factor. Nat. Struct. Biol. 2002, 9:680-684.
187. Ye X., Sun X., Starovoytov V., Cai Q. Parkin-mediated mitophagy in mutant hAPPneurons and Alzheimer's disease patient brains. Hum. Mol. Genet. 2015, (Feb 12). pii: ddv056.
188. Ying W., Alano C.C., Garnier P., Swanson R.A. NAD+ as a metabolic link between DNA damage and cell death. J. Neurosci. Res. 2005, 79:216-223.
189. Ying W., Chen Y., Alano C.C., Swanson R.A. Tricarboxylic acid cycle substrates prevent PARP-mediated death of neurons and astrocytes. J. Cereb. Blood Flow Metab.: Off. J. Int. Soc. Cereb. Blood Flow Metab. 2002, 22:774-779.
190. Yokoyama H., Kuroiwa H., Tsukada T., Uchida H., Kato H., Araki T. Poly(ADP-ribose) polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. J. Neurosci. Res. 2010, 88:1522-1536.
191. Youle R.J., van der Bliek A.M. Mitochondrial fission, fusion, and stress. Science 2012, 337:1062-1065.
192. Yu S.W., Wang H., Poitras M.F., Coombs C., Bowers W.J., Federoff H.J., Poirier G.G., Dawson T.M., Dawson V.L. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002, 297:259-263.
193. Yu Y.C., Kuo C.L., Cheng W.L., Liu C.S., Hsieh M. Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease. J. Neurosci. Res. 2009, 87:1884-1891.
194. Yu Y.M., Kim J.B., Lee K.W., Kim S.Y., Han P.L., Lee J.K. Inhibition of the cerebral ischemic injury by ethyl pyruvate with a wide therapeutic window. Stroke: J. Cereb. Circ. 2005, 36:2238-2243.
195. Zerfaoui M., Errami Y., Naura A.S., Suzuki Y., Kim H., Ju J., Liu T., Hans C.P., Kim J.G., Abd Elmageed Z.Y., Koochekpour S., Catling A., Boulares A.H. Poly(ADP-ribose) polymerase-1 is a determining factor in Crm1-mediated nuclear export and retention of p65 NF-kappa B upon TLR4 stimulation. J. Immunol. 2010, 185:1894-1902.
196. Zhang Y., Herman B. Ageing and apoptosis. Mech. Ageing. Dev. 2002, 123:245-260.
197. Zingarelli B., Hake P.W., O'Connor M., Denenberg A., Kong S., Aronow B.J. Absence of poly(ADP-ribose) polymerase-1 alters nuclear factor-kappa B activation and gene expression of apoptosis regulators after reperfusion injury. Mol. Med. 2003, 9:143-153.
198. Zuo L., Motherwell M.S. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease. Gene 2013, 532:18-23.